A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Next Previous
Trial Profile

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie

    • Most Recent Events

    • 18 Dec 2017 Planned primary completion date changed from 16 Dec 2017 to 17 May 2017.
    • 31 Oct 2017 Planned End Date changed from 16 Dec 2017 to 31 Jul 2018.
    • 29 Sep 2017 Planned End Date changed from 23 Sep 2017 to 16 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top